Use of biomarkers in risk assessment

International Journal of Hygiene and Environmental Health

Volumn 204, Issue 2-3, 2001, Pages 91-102

  Vainio, H ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Biomarkers; Cytogenetic effects; DNA adducts; Internal dose; Protein adducts; Risk assessment

Indexed keywords

BIOLOGICAL MARKER; ONCOPROTEIN;

CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CYTOGENETICS; DNA ADDUCT; ECOTOXICOLOGY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL HEALTH; GENE MUTATION; GENETIC POLYMORPHISM; HIGH RISK POPULATION; HUMAN; MOLECULAR GENETICS; OCCUPATIONAL TOXICOLOGY; ONCOGENE; REVIEW; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

EID: 0035175112     PISSN: 14384639     EISSN: None     Source Type: Journal    
DOI: 10.1078/1438-4639-00088     Document Type: Article

References (100)

1. Human monitoring for somatic mutation in humans
2. Future research directions for evaluating human genetic and cancer risk from environmental exposures
3. IPCS guidelines for the monitoring of genotoxic effects of carcinogens in humans. International Programme on Chemical Safety
4. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer
5. Immunohistochemical detection of pulmonary cytochrome P 450IA and metabolic activities associated with P450IA1 and P450IA2 isozymes in lung cancer patients
6. Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: Correlation with stage and rate of progression
7. Ras genes
8. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers
9. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer
10. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens
11. Biomarkers of gene expression: Growth factors and oncoproteins
12. Molecular markers of carcinogenesis
13. Serum oncoproteins and growth factors in asbestosis and silicosis patients
14. Mutant p21 protein as a biomarker of chemical carcinogenesis in humans
15. ErbB-2 protein in sera and tumors of breast cancer patients
16. Hemoglobin adducts of 4-aminobiphenyl in smokers and nonsmokers
17. Polymorphisms of the GSTP1 and GSTM1 genes and PAH-DNA adducts in human mononuclear white blood cells
18. Determination of CYPIA 2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites
19. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer
20. The use of 4-aminobiphenyl hemoglobin adducts and aromatic DNA adducts in lymphocytes of smokers as biomarkers of exposure
21. Detection of serum c-myc oncoprotein in cancer patients by immunoblot
22. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR 3 gene expression
23. Carcinogen adducts: Use in diagnosis and risk assessment
24. Apoptosis in cancer therapy: Crossing the threshold
25. Urinary mutagenicity on TA98 and YG1024 Salmonella typhimurium strains after a hamburger meal: Influence of GSTM 1 and NAT2 genotypes
26. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
27. Cancer risk estimation of genotoxic chemicals based on target dose and a multiplicative model
28. Molecular genetics of the N-acetyltransferases
29. Molecular genetics of lung cancer
30. Endpoints and surrogates for use in population studies in toxicology
31. Seasonal variation of aromatic DNA adducts in human lymphocytes and granulocytes
32. Catalytic selectivity of human cytochrome P450 enzymes: Relevance to drug metabolism and toxicity
33. Chromosomal aberrations in lymphocytes predict human cancer: A report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH)
34. Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke
35. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene
36. N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers
37. DNA adducts and mutations in occupational and environmental biomonitoring
38. Postlabeling and immunoassay analysis of polycyclic aromatic hydrocarbons - Adducts of deoxyribonucleic acid in white blood cells of foundry workers
39. Aromatic DNA adducts in foundry workers in relation to exposure, life style and CYP 1A1 and glutathione transferase M1 genotype
40. Dna adducts, mutations, and cancer 2000
41. Point-mutational MspI and IleVal polymorphisms closely linked in the CYP1A1 gene: Lack of association with susceptibility to lung cancer in a Finnish study population
42. Increased frequency of 6-thioguanine-resistant lymphocytes in peripheral blood of workers employed in cyclophosphamide production
43. Human CYP1A2: Sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression
44. Acetylation phenotype and cytochrome P450IA2 phenotype are unlikely to be associated with peripheral arterial disease
45. Benchmark guideline for urinary 1-hydroxypyrene as biomarker of occupational exposure to polycyclic aromatic hydrocarbons
46. Predictive value of molecular dosimetry: Individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer
47. p185neu expression in human lung adenocarcinomas predicts shortened survival
48. Some functions of glutathione transferases
49. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer
50. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: A case-series meta-analysis of a gene-environment interaction
51. Biologic markers in ethylene oxide-exposed workers and controls
52. Expression of CYP1A1 gene in patients with lung cancer: Evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas
53. Acetylator phenotype in human bladder cancer
54. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent
55. Metabolic polymorphisms as susceptibility markers for lung and oral cavity cancer
56. Effects of occupation, lifestyle and genetic polymorphisms of CYP1A1, CYP2E1, GSTM1 and GSTT1 on urinary 1-hydroxypyrene and 2-naphthol concentrations
57. Role of genetics and drug metabolism in human cancer risk
58. Human drug-metabolizing enzyme polymorphisms: Effects on risk of toxicity and cancer
59. Cytogenetic markers of susceptibility: Influence of polymorphic carcinogen-metabolizing enzymes
60. Biomonitoring of 1,3-butadiene and related compounds
61. Haemoglobin adducts as biomarkers of occupational exposure to 1,3-butadiene
62. Serum oncoproteins in asbestosis patients
63. The potential usefulness of biological markers in risk assessment
64. Molecular epidemiology: Insights into cancer susceptibility, risk assessment, and prevention
65. Response to DNA adducts as a marker of cancer risk?
66. Molecular and genetic damage in humans from environmental pollution in Poland
67. bcl-2 protein in non-small-cell lung carcinoma
68. Protein and DNA adducts as biomarkers of exposure to environmental mutagens
69. DNA adducts as exposure biomarkers and indicators of cancer risk
70. Genetic control of isoniazid metabolism in man
71. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer
72. Diet, acetylator phenotype, and risk of colorectal neoplasia
73. High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/Msp-GSTM1*0/*0 genotypes
74. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers
75. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer
76. Identification of p 53 gene mutations in bladder cancers and urine samples
77. Survival in operable nonsmall-cell lung cancer: Role of p53 mutations, tobacco smoking and asbestos exposure
78. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung
79. Metabolic polymorphisms and cancer susceptibility
80. Urinary mutagenicity in nonsmokers following exposure to fresh diluted sidestream cigarette smoke
81. Human cytogenetic damage as a predictor of cancer risk
82. Arylamine N-acetyltransferase as a potential biomarker in bladder cancer: Fluorescent in situ hybridisation and immunochemistry studies
83. Caffeine as a probe for CYP1A2 activity: Potential influence of renal factors on urinary phenotypic trait measurements
84. Biological and chemical monitoring of occupational exposure to ethylene oxide
85. Measurement of frequencies of HPRT mutants, chromosomal aberrations, micronuclei, sister-chromatid exchanges and cells with high frequencies of SCEs in styrene/dichloromethane-exposed workers
86. Human CYP1A1 (cytochrome P(1)450) gene: Lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population
87. Carcinogenicity and genotoxicity of ethylene oxide: New aspects and recent advances
88. Biological model of ED 01 hepatocarcinogenesis
89. Anti-p 53 antibodies in sera of workers occupationally exposed to vinyl chloride
90. Bacterial urinary assay in monitoring exposure to mutagens
91. Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool
92. Tobacco and cancer: Epidemiology and the laboratory
93. Genetically based Nacetyltransferase metabolic polymorphism and lowlevel environmental exposure to carcinogens
94. Persistence of O6-guanine DNA adducts in styrene-exposed lamination workers determined by 32P-postlabelling
95. An evaluation of styrene genotoxicity using several biomarkers in a 3-year follow-up study of handlamination workers
96. Exposure biomarkers in chemoprevention studies of liver cancer
97. Metabolic polymorphisms in carcinogen metabolizing enzymes and cancer susceptibility
98. Hemoglobin Adducts and Sister Chromatid Exchanges in Hospital Workers Exposed to Ethylene Oxide: Effects of Glutathione S-Transferase T 1 and M1 Genotypes
99. DNA adducts of 1,3-butadiene in humans: Relationships to exposure, GST genotypes, single-strand breaks, and cytogenetic end points